Loading
T cells engineered with a receptor that sees fragments of proteins inside the cancer cell, reaching targets CAR-T cannot.
Afamitresgene autoleucel (Tecelra) was the first approved TCR-T, for MAGE-A4+ HLA-A*02+ synovial sarcoma (2024, label expanded 2026). Letetresgene (NY-ESO-1) followed in trials. Neoantigen-specific TCR-T against KRAS G12D and TP53 hotspots (NCI Rosenberg) and PRAME-directed TCR-T (Immatics IMA203, phase 3 in melanoma) are the most watched.
Transgenic αβ TCR recognises a peptide-HLA complex; restricted to patients with the matching HLA allele.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.
TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.
The first drug to improve survival in metastatic uveal melanoma, and the first TCR-based bispecific.
Query for this technology: (TITLE:"TCR-T" OR ABSTRACT:"TCR-T" OR TITLE:"T cell receptor therapy" OR ABSTRACT:"T cell receptor therapy" OR TITLE:"TCR-engineered T cells" OR ABSTRACT:"TCR-engineered T cells"). Results are unfiltered search hits about TCR-T cell therapy, not a curated reading list.
Shares Public cell-therapy foundries at cancer centres for academics and start-ups, Patrick Hwu, Steven A. Rosenberg, Hospital-exemption cell therapies at scale, backed by a shared registry.
Shares TCR therapeutics for non-HLA-A*02 patients, HLA-A*02:01 restriction, PRAME, HLA-A.
Shares Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma, Letetresgene autoleucel, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma.
Shares Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer, QIMR Berghofer Medical Research Institute, Cell-therapy release and potency testing, Viral vector manufacturing (lentiviral, retroviral, AAV).
Shares HLA-A*02:01 restriction, Afamitresgene autoleucel, HLA-A, Tebentafusp.
Shares Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM), Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, PRAME, Tebentafusp.
Shares IGNYTE-ESO, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Steven A. Rosenberg, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Advanced melanoma (unresectable stage III and stage IV), Manufacturing cost and time for living and radioactive medicines.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Reconstructs T-cell and B-cell receptor repertoires from bulk or single-cell RNA-seq of tumours.
An R package for exploring immune receptor repertoires, from clonality to diversity.
T-cell and B-cell receptor analysis integrated with scanpy for tumour immune repertoires.
Distance-based analysis of T-cell receptor repertoires from the Fred Hutch, for grouping receptors that recognise the same antigens.